Abstract
Antiapoptotic molecules are important in the development, progression, and prognosis of malignant disorders. The aim of this study was to determine the expression of two distinct antiapoptotic molecules, SIRT1 and Survivin (SVV), in chronic myeloid leukemia (CML) and to compare them with hematological prognostic factors. In this study, we measured the expression of SVV and SIRT1 in 18 patients with typical Ph-positive chronic myeloid leukemia in chronic phases of the disease as well as in 18 matched healthy donors. SVV, SIRT1, and BCR/ABL expression were determined by quantitative-real-time polymerase chain reaction (Q-RT-PCR). HPRT was used as a reference gene to calculate SVV/HPRT and SIRT1/HPRT ratio, and ABL was used as an internal control for BCR/ABL expression. SVV was between 0.00 and 2.39-fold (median 0.204) and SIRT1 was between 0.00 and 33.32-fold (median 0.186). In our study, both SVV and SIRT1 were lower in patients than in the controls (p = 0.001 and 0.001, respectively). Although the expression of SVV and SIRT1 was decreased in patients with chronic phase (0.043 and 0.043-fold, respectively), a potent expression upregulation of both genes was found in K562, Jurkat, and U937 cell lines. Despite lower expression of both SVV and SIRT1 at chronic phase, a significant correlation was found between SVV expression levels and minor Hb concentration (<10) (p = 0.005). In addition, there was important correlation between BCR/ABL copy number and older age (≥60) and PLT count (p = 0.027 and p = 0.001, respectively). Of course, no specific clinicohematological or prognostic profile was associated with SIRT1 expression. In contrast with SIRT1 expression, high SVV expression and high BCR/ABL copy number could be introduced as prognostic factors in chronic phase of CML, but this finding must be evaluated in other phase of CML and with a higher number of subjects.
Similar content being viewed by others
References
Adida C, Recher C, Raffoux E, Daniel MT, Taksin AL, Rousselot P et al (2000a) Expression and prognostic significance of survivin in de novo acute myeloid leukaemia. Br J Haematol 111(1):196–203
Adida C, Haioun C, Gaulard P, Lepage E, Morel P, Briere J et al (2000b) Prognostic significance of survivin expression in diffuse large B-cell lymphomas. Blood 96(5):1921–1925
Ambrosini G, Adida C, Altieri DC (1997) A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 3(8):917–921
Badran A, Yoshida A, Wano Y, Imamura S, Kawai Y, Tsutani H et al (2002) Expression of the antiapoptotic gene survivin in chronic myeloid leukemia. Anticancer Res 23(1B):589–592
Badran A, Yoshida A, Wano Y, Mutoh M, Imamura S, Yamashita T et al (2003) Expression of the anti-apoptotic gene survivin in myelodysplastic syndrome. Int J Oncol 22(1):59–64
Bradbury C, Khanim F, Hayden R, Bunce C, White D, Drayson M et al (2005) Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors. Leukemia 19(10):1751–1759
Brunet A, Sweeney LB, Sturgill JF, Chua KF, Greer PL, Lin Y et al (2004) Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science 303(5666):2011–2015
Carter BZ, Milella M, Altieri DC, Andreeff M (2001) Cytokine-regulated expression of survivinin myeloid leukemia. Blood 97(9):2784–2790
Cheung CHA, Huang C-C, Tsai F-Y, Lee JY-C, Cheng SM, Chang Y-C et al (2013) Survivin–biology and potential as a therapeutic target in oncology. OncoTargets Ther 6:1453
Cohen HY, Miller C, Bitterman KJ, Wall NR, Hekking B, Kessler B et al (2004) Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase. Science 305(5682):390–392
Conte E, Stagno F, Guglielmo P, Scuto A, Consoli C, Messina A (2005) Survivin expression in chronic myeloid leukemia. Cancer Lett 225(1):105–110
Granziero L, Ghia P, Circosta P, Gottardi D, Strola G, Geuna M et al (2001) Survivin is expressed on CD40 stimulation and interfaces proliferation and apoptosis in B-cell chronic lymphocytic leukemia. Blood 97(9):2777–2783
Hernández-Boluda J-C, Bellosillo B, Vela M-C, Colomer D, Alvarez-Larrán A, Cervantes F (2005) Survivin expression in the progression of chronic myeloid leukemia: a sequential study in 16 patients. Leuk Lymphoma 46(5):717–722
Huang J, Lyu H, Wang J, Liu B (2015) Influence of survivin-targeted therapy on chemosensitivity in the treatment of acute myeloid leukemia. Cancer Lett 366(2):160–172
Jang KY, Hwang SH, Kwon KS, Kim KR, Choi HN, Lee N-R et al (2008) SIRT1 expression is associated with poor prognosis of diffuse large B-cell lymphoma. Am J Surg Pathol 32(10):1523–1531
Jang S-H, Min K-W, Paik SS, Jang K-S (2012) Loss of SIRT1 histone deacetylase expression associates with tumour progression in colorectal adenocarcinoma. J Clin Pathol 65(8):735–739
Jung W, Hong KD, Jung WY, Lee E, Shin BK, Kim HK et al (2013) SIRT1 expression is associated with good prognosis in colorectal cancer. Korean J Pathol 47(4):332–339
Kamihira S, Yamada Y, Hirakata Y, Tomonaga M, Sugahara K, Hayashi T et al (2001) Aberrant expression of caspase cascade regulatory genes in adult T‐cell leukaemia: survivin is an important determinant for prognosis. Br J Haematol 114(1):63–69
Kantarjian HM, Keating MJ, Smith TL, Talpaz M, McCredie KB (1990) Proposal for a simple synthesis prognostic staging system in chronic myelogenous leukemia. Am J Med 88(1):1–8
Li L, Wang L, Li L, Wang Z, Ho Y, McDonald T et al (2012) Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination with imatinib. Cancer Cell 21(2):266–281
Luo J, Nikolaev AY, Imai S-I, Chen D, Su F, Shiloh A et al (2001) Negative control of p53 by Sir2α promotes cell survival under stress. Cell 107(2):137–148
Martinez A, Bellosillo B, Bosch F, Ferrer A, Marcé S, Villamor N et al (2004) Nuclear survivin expression in mantle cell lymphoma is associated with cell proliferation and survival. Am J Pathol 164(2):501–510
Melo JV, Barnes DJ (2007) Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat Rev Cancer 7(6):441–453
Mobahat M, Narendran A, Riabowol K (2014) Survivin as a preferential target for cancer therapy. Int J Mol Sci 15(2):2494–2516
Mori N, Yamada Y, Hata T, Ikeda S, Yamasaki Y, Tomonaga M et al (2001) Expression of survivin in HTLV-I-infected T-cell lines and primary ATL cells. Biochem Biophys Res Commun 282(5):1110–1113
Mori A, Wada H, Nishimura Y, Okamoto T, Takemoto Y, Kakishita E (2002) Expression of the antiapoptosis gene survivin in human leukemia. Int J Hematol 75(2):161–165
Nakamura S, Takemura T, Tan L, Nagata Y, Yokota D, Hirano I et al (2011) Small GTPase RAB45-mediated p38 activation in apoptosis of chronic myeloid leukemia progenitor cells. Carcinogenesis 32(12):1758–1772
Nakayama K, Kamihira S (2002) Survivin an important determinant for prognosis in adult T-cell leukemia: a novel biomarker in practical hemato-oncology. Leuk Lymphoma 43(12):2249–2255
O’Dwyer ME, Mauro MJ, Kurilik G, Mori M, Balleisen S, Olson S et al (2002) The impact of clonal evolution on response to imatinib mesylate (STI571) in accelerated phase CML. Blood 100(5):1628–1633
Rahimian A, Soleimani M, Kaviani S, Aghaee-Bakhtiari S, Atashi A, Arefian E et al (2011) Bypassing the maturation arrest in myeloid cell line U937 by over-expression of microRNA-424. Hematology 16(5):298–302
Schlette EJ, Medeiros LJ, Goy A, Lai R, Rassidakis GZ (2004) Survivin expression predicts poorer prognosis in anaplastic large-cell lymphoma. J Clin Oncol 22(9):1682–1688
Thielen N, Ossenkoppele G, Schuurhuis G, Janssen J (2011) new insights into the pathogenesis of chronic myeloid leukaemia: towards a path to cure. Neth J Med 69(10):430–440
Vaziri H, Dessain SK, Eaton EN, Imai S-I, Frye RA, Pandita TK et al (2001) hSIR2SIRT1 functions as an NAD-dependent p53 deacetylase. Cell 107(2):149–159
Yuan H, Wang Z, Li L, Zhang H, Modi H, Horne D et al (2012) Activation of stress response gene SIRT1 by BCR-ABL promotes leukemogenesis. Blood 119(8):1904–1914
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
This study was approved by the local ethics committee of Ahvaz Jundishapur University of Medical Sciences and with the 1964 Helsinki Declaration. Written informed consent was obtained from all patients and normal individuals.
Conflict of interest
The authors declare that they have no competing interests.
Rights and permissions
About this article
Cite this article
Salari, F., Mohammdai-asl, J., Malehi, A.S. et al. Survivin and SIRT1: can be two prognostic factors in chronic myeloid leukemia?. Comp Clin Pathol 25, 415–420 (2016). https://doi.org/10.1007/s00580-015-2201-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00580-015-2201-1